Trial intelligence / Profile preview

Triheptanoin for the Preventive Treatment of Migraine

NCT02784847Phase 1Unknown

Sponsor
University of Liège
Start
Jun 2016
Primary completion
Nov 2016
Modality
SLNs, Nanostructured Lipid Carriers, Small Molecules
01

Overview

Phase 1, open-label, single-arm trial of triheptanoin in migraine, sponsored by University of Liège. Primary endpoint: Change in monthly migraine days at 3 months. Status: unknown.

02

Drugs

triheptanoin
03

Conditions

migraine

Beyond the preview

Go deeper on NCT02784847.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02784847.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call